



The ADORE Study: an international, phase 3, randomized, placebo-controlled trial with daily oral edaravone (FNP122) in ALS

Learn more about the ADORE study, which is researching the safety and efficacy of FNP122 for people living with ALS.

FNP122 is a newly developed oral liquid formulation of edaravone to be self-administered daily. This compound can help prevent oxidative stress, which is thought to contribute to nerve cell death in ALS, and potentially protect motor neurons. Therefore, by decreasing oxidative stress, edaravone could potentially slow ALS progression.

Study design

300 PATIENTS

2:1

FNP122:Placebo

The study will enroll 300 people living with ALS.

From now on, patients starting the trial will receive either FNP122 or placebo for 48 weeks.

Riluzole (100mg/day or less) may be used as background (add-on) therapy



Multicenter

Multinational

Double-blind

Randomized

Placebo-controlled

Several TRICALS Centers across Europe will participate in this trial

Key requirements to participate



You are diagnosed with ALS and between **18 – 80 years**



Your lung function is at least **70%** at the first visit of the study (screening visit)



You are within **24 months** of when you had your first symptoms

Low burden of study visit schedules



Short screening period
(max. 12 days)



6 hospital visits in 48 weeks
baseline, week 4 and every 3 months



Monthly calls

Extension study to receive daily oral edaravone after completing the ADORE STUDY

After 48 weeks all participants will be offered the possibility to roll over in an open label extension study to receive daily oral edaravone until the drug is available on the market

If you have any question regarding the ADORE Study please contact



info@tricals.org

TRICALS
The highway towards a cure

The ADORE Phase III clinical trial is being conducted with the support of TRICALS, the largest European research initiative to find a cure for ALS

Committed to **MAKING A POSITIVE IMPACT ON PATIENTS' LIVES** through the research, development and commercialization of transformative therapies, with an increasing focus on pulmonary vascular and interstitial lung diseases and neurological disorders

Certified

Corporation


ferrer
for good